Proteins bioprocessing

Hu, G., 2011. Understanding the fundamentals of peptides and proteins. BioProcessing Journal 10, 12-14. 

When compared to traditional chemical synthesis, processes based on biocatalysts are generally less reliable. This is due, in part, to the fact that biological systems are inherently complex. In bioprocesses involving whole cells, it is essential to use the same strain from the same culture collection to minimise problems of reproducibility. If cell free enzymes are used the reliability can depend on the purity of the enzyme preparation, for example iso-enzyme composition or the presence of other proteins. It is, therefore, important to consider the commercial source of the enzyme and the precise specifications of the biocatalyst employed. 

Carbazole, A-methylcarbazole, IV-ethylcarbazole, dibenzofuran, dibenzothiophene, fluorene, dibenzo-p-dioxin, phenoxathiin, phenoxazine, phenothiazine, xanthene, biphenyl, naphthalene, phenanthrene, anthracene, and fluoranthene could be transformed by E. coli, [314] which was transformed using a plasmid bearing the carAa, Ac, and Ad genes, and expressing only the carA-encoded proteins. Further work is needed to develop a final biocatalyst and to prove the advantages that this degradative pathway would incorporate in a refining bioprocess. 

HyClone is a supplier of cell culture and bioprocessing systems, which also offers customized work to configure particular applications. Services address activities, research, and production. Business is centered on culturing media, and consequently support is offer for the development of a given formulation. HyClone supplies FBS and other sera for cell culture, serum-free and protein-free media, etc. 

LSBC is highly active in protein and peptide commercialization, placing special emphasis on the development of protein therapeutics. LSBC s capabilities are two-fold, in one side, the company s protein expertise and in the other it s commercial-scale manufacturing in the plant-made bioprocessing. 

In this review, we focus on the use of plant tissue culture to produce foreign proteins that have direct commercial or medical applications. The development of large-scale plant tissue culture systems for the production of biopharmaceutical proteins requires efficient, high-level expression of stable, biologically active products. To minimize the cost of protein recovery and purification, it is preferable that the expression system releases the product in a form that can be harvested from the culture medium. In addition, the relevant bioprocessing issues associated with bioreactor culture of plant cells and tissues must be addressed. 

Decolorization of azo dyes by WRF technology improvements will require integration of all major areas of industrial biotechnology novel enzymes and microorganisms, functional genomics, protein engineering, biomaterial development, bioprocess design and applications. 

Hagman and Sivertsson discussed the work performed at Pharmacia and Upjohn52 on monitoring and controlling bioprocesses. They followed the protein production-derived form Chinese hamster cells (CHO-cells) in a 500-1 reactor over a 3-month period. The diagrams of the flow cell and pumping/NIR system are displayed, and the logic behind the work outlined. External and on-line calibrations were performed. 

The deconvolution of spectra is the topic of a paper by Vaidyanathan et al.58 The authors use the somewhat complex matrix of mycelial bioprocesses for a model. Throughout the reactions of five different unicellular microorganisms, biomass, external proteins, penicillin, T-sugars, and ammonium were measured vs. time. Each analyte was justified from spectral interpretation. The spectral range used was from 700 to 2500 nm, with specific regions used for each experiment. 

---